XSTAT 30 Package Insert

**NAME OF STUDY**  GLP EVALUATION OF XSTAT DRESSING IN A SWINE FEMORAL MODEL

**STUDY DESCRIPTION**  GLP animal study to demonstrate the performance of the XSTAT 30 Dressing compared to the XSTAT 30 Predicate dressing, using the United States Army Institute of Surgical Research ("USAISR") standard femoral animal injury.

**NUMBER OF SUBJECTS**
- Ten (10) animals were treated with the XSTAT dressing (Test Article)
- Ten (10) animals were treated with the XSTAT 30 predicate device (Control Article)

**INCLUSION / EXCLUSION**

- Inclusion
  - Animal breed: Landrace cross swine
  - Weight at procedure: 55-65 kg
  - Age at procedure: 3-5 months (appropriate to weight)

- Exclusion criteria included inappropriate vessel anatomy, persistently low MAP (< 55 mmHg) prior to femoral artery injury, and significant blood loss (>300 mL) because of surgical complication or error before femoral artery injury.

**STUDY PROCEDURE**

**ALL WOUNDS PRIOR TO RANDOMIZATION**

- An incision was created (3.5 cm long) through the skin and subcutaneous tissues in the groin area directly over the left femoral artery and an approximately 3 cm section of femoral artery was exposed.
- The femoral artery was covered with a small piece of gauze and bathed with 2% lidocaine HCl solution to relax the vasospasm and dilate the artery to a 5 mm outer diameter.
- Non-traumatic vessel loops were placed proximally and distally on the femoral artery.
- Using a 6.0 mm vascular punch, an arteriotomy was created.
- The vessel loops were released, the injury start time was recorded and the vessel was allowed to bleed freely for 45 seconds before the Test (XSTAT) or Control Article (XSTAT 30) was applied.
- The vessel loops were allowed to remain in the wound to facilitate hemorrhage control during test material removal.

**WOUNDS RANDOMIZED TO XSTAT Dressing (Test Article)**

- XSTAT dressing was applied as per product instructions for use (IFU) starting immediately following the 45-second free bleed.
- XSTAT was applied as quickly as possible and as many as necessary until the bleeding has stopped, or until the 5-minute limit, whichever was sooner.
- A cloth bandage was wrapped around the limb and firmly secured over the packed wound.
- Manual pressure was permitted if bleeding persisted following application of the dressing as per the IFU.

**WOUNDS RANDOMIZED TO XSTAT 30 Predicate (Control Article)**

- XSTAT 30 dressing was applied as per product instructions for use (IFU) starting immediately following the 45-second free bleed.
- XSTAT 30 dressing was applied as quickly as possible and as many as necessary until the bleeding stopped, until the 5-minute limit, whichever was sooner.
- A cloth bandage was wrapped around the limb and firmly secured over the packed wound.
- Manual pressure was permitted if bleeding persisted following application of the dressing as per the IFU.

**POST-RANDOMIZATION CARE**

- Resuscitation began 5-25 minutes post-injury (i.e., free bleed start time) by infusing colloidal fluid (Hetastarch) at a target volume of 500mL into the jugular vein.
- Resuscitation was continued, if necessary, with pre-warmed lactated Ringer's solution (LRS). The total volume of LRS infused was based on pre-and post-use weights of the LRS infusion bags, assuming 1 g – 1 mL. The actual rate was then based on the volume of LRS divided by the duration of infusion for each bag. If the MAP dropped to ~ 60 mmHg or less, LRS was infused into the jugular vein and discontinued when the MAP of at least 65 mmHg was reached.
- Following the 6-hour observation period, the Test or Control Article was removed from the wound site and the animal euthanized.
- XSTAT minisponges were removed from the wound site manually as well as with surgical forceps for both animals treated with test and control articles.
- Following sponge removal and euthanasia, the wound site was imaged using a portable fluoroscopy unit.

**RESULTS**

**ENDPOINTS**

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>XSTAT (Test Article)</th>
<th>XSTAT 30 (Control Article)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1: Bleeding Time, mean: Duration of bleeding (visible blood shed from the wound site) occurring at any time immediately following test material application until was at exsanguination or end of the 6-hour observation period.</td>
<td>1.8 (5.7) minutes</td>
<td>1.6 (3.7) minutes</td>
</tr>
<tr>
<td>2: Post-Treatment Blood Loss, mean (stddev): Amount of blood shed from the wound cavity during the time period following the dressing application until exsanguination or end of the 6-hour observation period.</td>
<td>0.1 (0.2) mL/kg</td>
<td>1.0 (3.0) mL/kg</td>
</tr>
<tr>
<td>3: Final Mean Arterial Pressure (MAP), mean (stddev): Mean arterial pressure recorded just prior to exsanguination or end of the 6-hour observation period.</td>
<td>66 (4) mmHg</td>
<td>65 (3) mmHg</td>
</tr>
<tr>
<td>4: Survival Time, mean (stddev): Time period immediately following the 45 second free bleed during which vital signs are; MAP &gt;20 mmHg and PCO2 &gt;15 mmHg to exsanguination or end of the 6-hour observation period.</td>
<td>5.45 (0.00) hours</td>
<td>5.46 (0.01) hours</td>
</tr>
<tr>
<td>5: Percentage Survival: Percentage of animals surviving to the end of the study observation period (6-hours) for a given treatment, where survival was defined as the MAP &gt;20 mmHg and PCO2 &gt;15 mmHg.</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>

The presence or absence of distal limb ischemia was not assessed in this study. There was no postmortem evidence of blood tracking beneath the skin.

**Observations from Animal Study**

Pre-clinical studies of device performance of deployment and surgical removal of XSTAT sponges demonstrated that not all minisponges expanded during successful tamponade of the bleeding site and that some sponges may fall from the wound outside the body or may be retained in the applicator. Comprehensive accounting for mini-sponges deployed and retrieved from wounds may be inexact. In a pre-clinical animal study, a minisponge retained in the wound was not initially recognized by the veterinary surgical team but was identified on subsequent review.

Go to www.revmedx.com for training video and product information.
<table>
<thead>
<tr>
<th>NAME OF STUDY</th>
<th>EVALUATION OF XSTAT DRESSING IN A SWINE SUBCLAVIAN MODEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY DESCRIPTION</td>
<td>GLP animal study to demonstrate the performance of the XSTAT Dressing compared to the XSTAT 30 Predicate dressing, using the United States Army Institute of Surgical Research (“USAISR”) standard subclavian animal injury.</td>
</tr>
<tr>
<td>NUMBER OF SUBJECTS</td>
<td>Ten (10) animals treated with XSTAT dressing (Test Article) and Ten (10) animals treated with XSTAT 30 predicate device (Control Article)</td>
</tr>
</tbody>
</table>
| INCLUSION / EXCLUSION | • Inclusion 
  o Animal Breed: Landrace cross swine 
  o Weight at procedure: 41-62 kg 
  o Age at procedure: 3.5 months (appropriate to weight) 
  • Exclusion criteria included inappropriate vessel anatomy, persistently low MAP (< 55 mmHg) prior to femoral artery injury, and significant blood loss (>300 mL) because of surgical complication or error before femoral artery injury. |
| STUDY PROCEDURE | ALL WOUNDS PRIOR TO RANDOMIZATION 
• An incision was created (5.0 cm long) through the skin and subcutaneous tissues over the left superficial pectoralus directly over the left subclavian artery and an approximately 4.0 cm section of subclavian artery was exposed. 
• The femoral artery was covered with a small piece of gauze and bathed with 2% lidocaine HCl solution to relax the vasospasm and dilate the artery to ≥ 5 mm outer diameter. 
• The subclavian artery and vein were transected and allowed to bleed freely for 30 seconds. 

WOUNDS RANDOMIZED TO XSTAT Dressing (Test Article) 
• XSTAT dressing was applied as per product instructions for use (IFU) starting immediately following the 30-second free bleed. 
• XSTAT was applied as quickly as possible and as many as necessary until the bleeding has stopped, or until the 5 -minute limit, whichever was sooner. 
• At the discretion of the surgeon, a cloth bandage was wrapped around the limb and firmly secured over the packed wound. 
• Manual pressure was permitted if bleeding persisted following application of the dressing as per the IFU. 

WOUNDS RANDOMIZED TO XSTAT 30 Predicate (Control Article) 
• XSTAT 30 dressing was applied as per product instructions for use (IFU) starting immediately following the 30-second free bleed. 
• XSTAT 30 dressing was applied as quickly as possible and as many as necessary until the bleeding stopped, until the 5 minute limit, whichever was sooner. 
• At the discretion of the surgeon, a cloth bandage was wrapped around the limb and firmly secured over the packed wound. 
• Manual pressure was permitted if bleeding persisted following application of the dressing as per the IFU. 

POST-RANDOMIZATION CARE 
• Resuscitation began 5-25 minutes post-injury (i.e., free bleed start time) by infusing colloidal fluid (Hetastarch) at a target volume of 500 mL into the jugular vein. 
• Resuscitation continued, if necessary, with pre-warmed lactated Ringer’s solution (LRS). The total volume of LRS infused was based on pre-and post-use weights of the LRS infusion bags, assuming 1 g – 1 mL. The actual rate was then based on the volume of LRS divided by the duration of infusion for each bag. If the MAP dropped to ~ 60 mmHg or less, LRS was infused into the jugular vein and discontinued when the MAP of at least 65 mmHg was reached. 
• Following the 1 hour observation period, the Test or Control Article was removed from the wound site and the animal euthanized. 
• XSTAT minisponges were removed from the wound site manually as well as with surgical forceps for both animals treated with test articles and control articles. 
• Following sponge removal and euthanasia, the wound site was imaged using a portable fluoroscopy unit. |
<table>
<thead>
<tr>
<th>RESULTS</th>
<th>ENDPOINTS</th>
<th>XSTAT (Test Article)</th>
<th>XSTAT 30 (Control Article)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1: Bleeding Time, mean: Duration of bleeding (visible blood shed from the wound site) occurring at any time immediately following test material application until was at exanguination or end of the 6-hour observation period.</td>
<td>0.7 (0.2) minutes</td>
<td>0.9 (2.9) minutes</td>
<td></td>
</tr>
<tr>
<td>2: Post-Treatment Blood Loss, mean (stdev): Amount of blood shed from the wound cavity during the time period following the dressing application until exanguination or end of the 6-hour observation period.</td>
<td>0.07 (0.03) mL/kg</td>
<td>0.2 (0.6) mL/kg</td>
<td></td>
</tr>
<tr>
<td>3: Final Mean Arterial Pressure (MAP), mean (stdev): Mean arterial pressure recorded just prior to exanguination or end of the 6-hour observation period.</td>
<td>65 (5) mmHg</td>
<td>68 (4) mmHg</td>
<td></td>
</tr>
<tr>
<td>4: Survival Time, mean (stdev): Time period immediately following the 45 second free bleed during which vital signs are; MAP ≥20mmHg and PCO2 ≥15 mmHg to exsanguination or end of the 6-hour observation period.</td>
<td>1:00 (0:00) hours</td>
<td>1:01 (0:03) hours</td>
<td></td>
</tr>
<tr>
<td>5: Percentage Survival: Percentage of animals surviving to the end of the study observation period (6 hours) for a given treatment, where survival was defined as the MAP ≥20 mmHg and PCO2 ≥15 mmHg.</td>
<td>100%</td>
<td>100%</td>
<td></td>
</tr>
</tbody>
</table>

The presence or absence of distal limb ischemia was not assessed in this study. There was no postmortem evidence of blood tracking beneath the skin.
**NAME OF STUDY**

**USER EVALUATION OF XSTAT 30 APPLICATION**

**STUDY DESCRIPTION**

A user evaluation (human factors) was completed to determine the ability of medics and civilian EMS and medical professionals to understand and execute instructions for using XSTAT 30 and applying XSTAT 30 on a simulated casualty.

**NUMBER OF SUBJECTS**

11

**INCLUSION/EXCLUSION**

Military or civilian EMS/Medical Professionals with no prior knowledge or experience with XSTAT dressing prior to the study.

**STUDY PROCEDURE:**

- A medical mannequin torso served as a wound model.
- The wound track – located in the upper thigh region approximately 5 cm distal to the iliac artery – had a diameter of 11 mm.
- Participants were evaluated on the ability to open the package, apply the applicator into the wound and deploy three (3) XSTAT 30 devices. In addition, participants were evaluated on the time needed to ready the device for use and deploy the device. Participants provided their evaluation on the use of the device, the packaging and Instructions for Use of the device, and the Training Video for the device.

**RESULTS**

<table>
<thead>
<tr>
<th>PARTICIPANT</th>
<th>TIME</th>
<th>USER COMMENTS</th>
<th>ACTIONS TAKEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>36</td>
<td>Add detail on resistance when using device; improve outer packaging</td>
<td>Statement regarding resistance included in IFU and training video; final package labeled with easy open tear notches.</td>
</tr>
<tr>
<td>3</td>
<td>39</td>
<td>Show areas where device is not indicated</td>
<td>Final training video comprises images highlighting areas that are contraindicated.</td>
</tr>
<tr>
<td>4</td>
<td>34</td>
<td>Include real and animation in video if possible; improve outer packaging</td>
<td>Final training video comprises mostly animation; final package labeled with easy open tear notches.</td>
</tr>
<tr>
<td>5</td>
<td>30</td>
<td>Improve outer packaging</td>
<td>Final package labeled with easy open tear notches.</td>
</tr>
<tr>
<td>6</td>
<td>33</td>
<td>Improve outer packaging</td>
<td>Final package labeled with easy open tear notches.</td>
</tr>
<tr>
<td>7</td>
<td>38</td>
<td>Improve outer packaging</td>
<td>Final package labeled with easy open tear notches.</td>
</tr>
<tr>
<td>8</td>
<td>53</td>
<td>IFU and packaging should hold up to rain and wind conditions.</td>
<td>Final IFU printed on water resistant material and tested for water exposure and legibility.</td>
</tr>
<tr>
<td>9</td>
<td>46</td>
<td>Ensure proper pronunciation in video; improve outer packaging; make plunger brighter</td>
<td>Pronunciation of key medical terms confirmed; final package labeled with easy open tear notches; final plunger is white.</td>
</tr>
<tr>
<td>10</td>
<td>39</td>
<td>IFU conveys steps to assure removal, median*</td>
<td>Package updated to include number of sponges per applicator.</td>
</tr>
<tr>
<td>11</td>
<td>53</td>
<td>Improve outer packaging</td>
<td>Final package labeled with easy open tear notches.</td>
</tr>
</tbody>
</table>

**NAME OF STUDY/CITED PUBLICATION**

**USER EVALUATION OF XSTAT DRESSING REMOVAL**

**STUDY DESCRIPTION**

A user evaluation was completed to assess the ability of surgeons to understand and execute instructions for removing XSTAT sponges from human cadaver wounds.

**NUMBER OF SUBJECTS**

4 surgeons; 1 cadaver; 2 wounds; 2 tests/wound

**INCLUSION / EXCLUSION**

Inclusion: civilian or military surgeon with no prior experience with XSTAT prior to the study

**STUDY PROCEDURE**

- Junctional wounds were made in each shoulder the cadaver
- Saline solution was circulated through cadaver’s vasculature to simulate blood flow.
- Following application of 2 XSTAT devices into the shoulder wounds, each surgeon was handed draft instructions for use and instructed to treat the wound.

**RESULTS**

<table>
<thead>
<tr>
<th>ENDPOINT</th>
<th>RESULT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Labeling clear on use of XSTAT device (Yes / No)</td>
<td>45</td>
</tr>
<tr>
<td>2. Completed all steps in IFU without assistance (Yes / No)</td>
<td>31</td>
</tr>
<tr>
<td>3. IFU conveys necessity of removal of sponges, median*</td>
<td>47</td>
</tr>
<tr>
<td>4. IFU conveys steps to assure removal, median*</td>
<td>20</td>
</tr>
<tr>
<td>5. Effective order of removal steps, median*</td>
<td>43</td>
</tr>
<tr>
<td>6. Ease of removal of sponges, median*</td>
<td>71</td>
</tr>
</tbody>
</table>

*Scale: 1 = Poor, 2 = Fair, 3 = Acceptable, 4 = Good, 5 = Very Good

**USER COMMENTS/ACTIONS TAKEN**

- Add reminder that all sponges must be removed before wound closure. | Package label and casualty card contain explicit instructions for surgical sponge removal. |
- Note approximate number of sponges per applicator on the package. | Package updated to include number of sponges per applicator. |

**XSTAT 30 TRAINING INFORMATION**

XSTAT 30 is a hemostatic dressing for the control of severe, life-threatening bleeding from junctional wounds in the groin or axilla not amenable to tourniquet application in adults and adolescents.

XSTAT 30 is a temporary dressing for use up to four (4) hours until surgical care is acquired. XSTAT should only be used for patients at high risk for immediate life-threatening bleeding from, hemodynamically significant (Advanced Trauma Life Support class 3 or 4 hemorrhagic shock), non-compressible junctional wounds or narrow entrance extremity wounds, and when definitive care at an emergency care facility cannot be achieved within minutes.

XSTAT 30 is NOT indicated for use in: the thorax, the pleural cavity, the mediastinum, the abdomen, the retroperitoneal space, the sacral space; tissues above the inguinal ligament, or tissues above the clavicle.

XSTAT 30 contains rapidly expanding cellulose sponges and individually marked with an X-shaped radiopaque marker. XSTAT 30 works by applying the small sponges into a wound cavity using a lightweight applicator. In the wound, the XSTAT 30 sponges expand and create a barrier to blood flow, present a large surface area for clotting, and provide gentle pressure.

The XSTAT 30 applicator is comprised of three primary parts:
- The main applicator which holds approximately 92 XSTAT sponges
- A telescoping handle
- A bifurcated silicone tip that allows the XSTAT to exit

Go to [www.revmedx.com](http://www.revmedx.com) for training video and product information.
**XSTAT 30 TRAINING INFORMATION CONTINUED**

XSTAT is a hemostatic dressing for the control of bleeding from junctional wounds in the groin or axilla or narrow entrance extremity wounds in the arms or legs. In narrow, deep wounds, XSTAT works by expansion of cellulose sponges against the walls of the cavity to apply pressure inside the wound.

Prior to using XSTAT, fully examine the injured patient and assess for signs of bleeding. Arterial bleeding is caused by the laceration of an artery and is the most difficult type of blood loss to control. Arterial hemorrhage is characterized by spurting blood that is bright red in color. Even a small, deep, arterial puncture wound can produce significant blood loss.

If the wound is not amenable to tourniquet use and is located on the groin or axilla, it is a junctional wound. In the testing of the XSTAT dressing, hemorrhage from the groin was created in a swine using a 6.0mm vascular punch on the femoral artery. The injury bled for 45 seconds prior to device application. The XSTAT dressing would be appropriate for use under comparable conditions.

If the hemorrhage cannot be identified or the anatomical location is not a junctional or extremity wound, XSTAT is not the preferred dressing to achieve hemorrhage control and alternative treatments should be used such as other hemostatic dressings or tourniquets.

XSTAT is NOT indicated for use in: the thorax, the abdomen, the retroperitoneal space, the sacral space; tissues above the inguinal ligament, or tissues above the clavicle.

XSTAT has not been tested for use in extremity wounds that are amenable to tourniquet application. XSTAT use in conjunction with tourniquet application has not been assessed for use in extremity wounds that are amenable to tourniquet application.

**WARNING:**

Prior to wound closure, obtain plane X-ray optimally in more than one projection. The presence of retained sponge may be easily missed on radiographic images. Thoroughly examine X-ray for radiopaque x-pattern of sponges or any triangular segments of the applicator tip that may be inadvertently retained in the wound cavity.

Confirmation of complete removal from the wound by X-ray is required to search for possible retained minisponges.

Review of X-rays to identify potential retained XSTAT minisponges should be performed by physicians trained to review surgical X-rays.

**WARNING:**

While the minisponges are designed with an X-pattern radio-opaque marker, it may be confused with other radio-opaque material in the wound, such as bone chips and wound clips.

---

**XSTAT DRESSING REMOVAL:**

- Survey the wound site and assess potential vascular bleeding sites and develop plan to achieve surgical control of injured vessel(s).
- Remove sponges from the wound site manually and/or with surgical forceps to the site(s) of bleeding.
- Thoroughly explore wound and removal all sponges.
- Prior to wound closure, obtain plane X-ray optimally in more than one projection. The presence of retained sponge may be easily missed on radiographic images. Thoroughly examine X-ray for radiopaque x-pattern of sponges or any triangular segments of the applicator tip that may be inadvertently retained in the wound cavity.
- If sponges or applicator tip segments are identified via X-ray, carefully re-examine wound cavity and remove sponges. Perform and review second X-ray to confirm complete sponge removal.

**WARNING:**

1. Relying upon sponge count alone post removal is not an accurate means of determining complete minisponge removal from the wound.
2. Careful surgical exploration of the wound site is required to ensure complete sponge removal from the wound.
3. Confirmation of complete removal from the wound by X-ray is required to search for possible retained minisponges.
4. Review of X-rays to identify potential retained XSTAT minisponges should be performed by physicians trained to review surgical X-rays.
5. While the minisponges are designed with an X-pattern radio-opaque marker, it may be confused with other radio-opaque material in the wound, such as bone chips and wound clips.